Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive results from a Phase 2 clinical trial of its drug eRapa in treating Familial Adenomatous Polyposis (FAP). The trial, which was partially funded by a $20 million grant from the Cancer Prevention and Research Institute of Texas, showed an 83% non-progression rate and a statistically significant decrease in overall mean polyp burden at 6 months. The results are scheduled for presentation at the 2024 Digestive Disease Week annual meeting in Washington D.C. The open-label study involved 30 adult patients across seven U.S. centers, with three different dosing cohorts over a 12-month treatment period. The primary endpoints were safety, tolerability, and percentage change from baseline in polyp burden at six months. The drug...Show More